label int64 1 1 | id stringlengths 10 12 | original_id stringlengths 8 9 | text stringlengths 347 29.5k |
|---|---|---|---|
1 | 171162302_b0 | 171162302 | employees who have a significant role in the Company's internal control over financial
reporting.
Date: April 4, 2016
By: /s/ MATTHEW KAPUSTA
Name: Matthew Kapusta
Title: Chief Financial Officer
1
EXHIBIT 13.1
Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Secti... |
1 | 171162302_b1 | 171162302 | preparation of financial statements for external purposes in accordance with generally accepted
accounting principles
c.
Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as... |
1 | 171162640_0 | 171162640 | EDAP TMS SA
Form 20-F
Filed on 04-Apr-2016 Period 31-Dec-2015 Accession number: 0001171843-16-008991
Included Items
1. 20-F: FORM 20-F 2. EX-1.1: EXHIBIT 1.1 3. EX-4.1: EXHIBIT 4.1 4. EX-4.2: EXHIBIT 4.2 5. EX-8.1.: EXHIBIT 8.1 6. EX-12.1: EXHIBIT 12.1 7. EX-12.2: EXHIBIT 12.2 8. EX-13.1: EXHIBIT 13.1 9. EX-15.1: EXH... |
1 | 171162640_1 | 171162640 | OR
ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2015
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________
OR
SHELL COMPANY REPORT PURSUANT TO SE... |
1 | 171162640_2 | 171162640 | Lamartine, 4/6, rue du Dauphiné, 69120 Vaulx-en-Velin, France (Name, Telephone, E-mail and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class American Depositary Shares, each representing
One Ordinary Share Ordinary Shares, nominal val... |
1 | 171162640_3 | 171162640 | the Securities Exchange Act of 1934.
Yes ____ No X
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such repo... |
1 | 171162640_b0 | 171162640 | 415) (1,415) (1,415) 1,692 0 202 0
1,747 2,335 1,031 5,113 15 5,128 (2,490) 2,638 (1,097) (1,587) (657) (3,342) (704) 6,769 38 1,251 645
Schedule of Valuation accounts (Details) - EUR ()
in Thousands
12 Months Ended Dec. 31, 2015 Dec. 31, 2014 Dec. 31, 2013 Dec. 31, 2012
Inventory Valuation Reserve [Member]
Valu... |
1 | 171162640_b1 | 171162640 | ,444
Other Revenue, Net
32
Total revenues
8,476
Total cost of sales
(3,636)
Gross margin
4,841
Research and development expenses
(1,387)
Selling and marketing expenses
(2,284)
General and administrative expenses
(646)
Total expenses
(4,318)
Operating income (loss)
523
Total assets
9,619
Capital exp... |
1 | 171170933_0 | 171170933 | Form 20-F
Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 20-F
¨
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC... |
1 | 171170933_1 | 171170933 |
Biotech plc (Exact name of Registrant as specified in its charter and translation of Registrant<U+0092>s name into English)
Ireland (Jurisdiction of
incorporation or organization) IDA Business Park, Bray, Co. Wicklow, Ireland
(Address of principal executive offices)
Kevin Tansley Chief
Financial Of... |
1 | 171170933_2 | 171170933 | to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuer<U+0092>s classes of capital or common stock as of the close of the period covered
by th... |
1 | 171170933_3 | 171170933 | of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨ Indicate by check mark
whether the registrant has submitted electronically... |
1 | 171170933_b0 | 171170933 | System Materials License Agreement dated as of April 18, 2005 (included as Exhibit 4.20 to our Annual Report on Form 20-F (File No. 000- 22320), filed with
the SEC on March 25, 2015).
4.21
Inverness Medical Innovations, Inc. Patent License Agreement renewal dated as of August 3, 2006 (included as Exhibit ... |
1 | 171170933_b1 | 171170933 | 20), filed with the SEC on March 25, 2015).
4.17
Lease agreement dated as of December 1, 2007 between 60 Pineview LLC with Immco Diagnostics Inc in respect of office premises in Amherst, New York, U.S.A. (included as Exhibit 4.17
to our Annual Report on Form 20-F (File No. 000- 22320), filed with the SEC o... |
1 | 171174771_0 | 171174771 | Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 20-F
... |
1 | 171174771_1 | 171174771 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
o
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report<U+0085><U+0085><U+0085><U+0085><U+0085>
Comm... |
1 | 171174771_2 | 171174771 | line Drive, Suite 350
Hawthorne, NY 10532(Name, Telephone, E-mail and/or Facsimile Number and Address of Company Contact Person)
Securities
registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class
Name of each exchange on which registered
Ordinary share... |
1 | 171174771_3 | 171174771 | the close of the period covered by the annual report.
Ordinary shares: 46,871,734
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
o Yes ý No
If this report is an annual or transition report, in... |
1 | 171174771_b0 | 171174771 | company Aditech Pharma AB (together with its
successor-in-interest, a Swiss company Aditech Pharma AG, "Aditech"), controlled by NB, began developing and filing patents for, among other things, formulations and dosing regimens of DMF. In 2005,
the Company entered into a patent license agreement with Aditech to lic... |
1 | 171174771_b1 | 171174771 | the tax liabilities arising from
the tax group or any entity participating in the tax group. The accompanying financial statements do not include a provision for any loss that may result from this contingency. See Notes 2.5
and 5.1.
The
German tax authorities commenced an audit of the tax returns of ... |
1 | 171180982_0 | 171180982 | 20-F
Table of Contents
SECURITIES AND EXCHANGE
COMMISSION Washington, D.C. 20549
FORM 20-F
¨
REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 193... |
1 | 171180982_1 | 171180982 |
CGG
(Exact name of registrant as specified in its charter)
CGG
(Translation of registrant<U+0092>s name into English)
Republic of France (Jurisdiction of incorporation or organization) Tour Maine
Montparnasse 33, avenue du Maine 75015 Paris France (Address of principal executive
offices) Stephan... |
1 | 171180982_2 | 171180982 | per share
New York Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) of the Act.
None
(Title of class) Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. 7.75% Senior Notes due 2017 6.50% Senior Notes due 2021
6.875% Senior Notes d... |
1 | 171180982_3 | 171180982 | of the Securities Exchange Act of 1934. Yes ¨ No x
Note <U+0097> checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934 from their obligations under those sections. Indicate by check mark whether the
registrant... |
1 | 171180982_b0 | 171180982 |
<U+0097>
(2.7
)
(2.7
)
Cash at opening
1,289.8
67.6
8.8
154.0
<U+0097>
1,... |
1 | 171180982_b1 | 171180982 |
(2.1
)
(37.4
)
(914.7
)
(197.1
)
Effect of exchange rates on cash
<U+0097>
<U+0097>
<U+0097>
<U+0097>
21.4
21.4
Impact of changes in consolidation scope
<U+00... |
1 | 171181846_0 | 171181846 | Form 20-F
Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 20-F
(Mark One)
¨
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E... |
1 | 171181846_1 | 171181846 |
Ascendis
Pharma A/S (Exact name of Registrant as specified in its charter and translation of Registrant<U+0092>s name into English)
The Kingdom of Denmark
(Jurisdiction of incorporation or organization)
Tuborg Boulevard 5
DK-2900 Hellerup, Denmark
(Address of principal executive offices)
J... |
1 | 171181846_2 | 171181846 | shares, nominal value DKK 1 per share*
The NASDAQ Stock Market LLC
The NASDAQ Stock Market LLC*
*
Not for trading, but only in connection with the registration of the American Depositary Shares.
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which... |
1 | 171181846_3 | 171181846 | ) of the Securities Exchange Act of 1934. ¨ Yes x No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file s... |
1 | 171181846_b0 | 171181846 | We have entered into indemnification agreements with our board members and members of our
senior management. Except for the information disclosed above, we have not undertaken any significant transactions with members of the
Board of Directors, our senior management or the major shareholders, or undertakings in whi... |
1 | 171181846_b1 | 171181846 | is a general partner of Sofinnova Ventures.
(3)
Albert Cha, M.D., Ph.D., a member of our board of directors, is a managing partner of Vivo Capital.
We entered into a registration rights agreement in November 2014 with certain holders of our ordinary shares, including Sofinnova Capital V
FCPR, Sofinnova Venture Pa... |
1 | 171193535_0 | 171193535 | 20-F
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 20-F
¨
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES... |
1 | 171193535_1 | 171193535 | number 001-35408
AVG
TECHNOLOGIES N.V. (Exact name of Registrant as specified in its charter and translation of Registrant<U+0092>s name into English)
The Netherlands
(Jurisdiction of incorporation or organization)
Gatwickstraat 9-39, 1043
GL Amsterdam, The Netherlands
(Address of principal... |
1 | 171193535_2 | 171193535 | icate the number of outstanding shares of each of the issuer<U+0092>s classes of capital or common stock as of the close of the period covered
by the annual report.
Title of each class
Number of shares
outstanding
Ordinary shares
51,628,104
Indicate by check mark if the registrant is a wel... |
1 | 171193535_3 | 171193535 | 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. x Yes ¨ No
Indicate by check mark whether the registrant has submitt... |
1 | 171193535_b0 | 171193535 | announced that it has adopted an additional share repurchase program under which it intends to repurchase
up to 500,000 of its ordinary shares (the <U+0093>shares<U+0094>) to cover the Company<U+0092>s obligations to deliver shares under its employee stock options incentive and restricted share units plans.
The sha... |
1 | 171193535_b1 | 171193535 | Board upon appointment by the General Meeting of Shareholders,
after which Mr. Little will resign as a member of the Management Board and continue his employment with the Company during the transition process. The Supervisory Board of the Company will nominate Mr. Ross for appointment to the
Company<U+0092>s Managem... |
1 | 171199018_0 | 171199018 | Adecoagro S.A.
Form 20-F
Filed on 27-Apr-2016 Period 31-Dec-2015 Accession number: 0001672764-16-000005
Included Items
1. 20-F: FORM 20-F 2. EX-8.1: EXHIBIT 8.1 3. EX-12.1: EXHIBIT 12.1 4. EX-12.2: EXHIBIT 12.2 5. EX-13.1: EXHIBIT 13.1 6. EX-13.2: EXHIBIT 13.2 7. EX-15.1: EXHIBIT 15.1 8. EX-15.2: EXHIBIT 15.2
UNITE... |
1 | 171199018_1 | 171199018 | AL YEAR ENDED ON DECEMBER 31, 2015 OR
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM
TO
OR
¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
COMM... |
1 | 171199018_2 | 171199018 | Name, Telephone, E-Mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of Each Class Common Shares
Name of Each Exchange on Which Registered New York Stock Exchange
Securities registered or to be registered pursuant... |
1 | 171199018_3 | 171199018 | Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes þ No ¨ Indicate by check mark whether the registrant has submitted electronically and posted on its corpo... |
1 | 171199018_b0 | 171199018 | such officer's knowledge that:
The annual report on Form 20-F for the fiscal year ended December 31, 2015 (the "Form 20-F") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material re... |
1 | 171199018_b1 | 171199018 | (d) of the Securities Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: April 27, 2016
/s/ Mariano Bosch Name: Mariano Bosch Title: Chief Executive Officer
A signed original of this written ... |
1 | 171199997_0 | 171199997 | Nabriva Therapeutics AG
Form 20-F
Filed on 28-Apr-2016 Period 31-Dec-2015 Accession number: 0001104659-16-114959
Included Items
1. 20-F 2. EX-1.2 3. EX-1.3 4. EX-4.12 5. EX-8.1 6. EX-12.1 7. EX-12.2 8. EX-13.1 9. EX-15.1
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM ... |
1 | 171199997_1 | 171199997 | from
to
OR
o SHELL COMPANY PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report...................
Commission file number: 001-37558
Nabriva Therapeutics AG
(Exact name of Registrant as specified in its charter and translation of Registrant's na... |
1 | 171199997_2 | 171199997 | .00 per share
Name of each exchange on which registered The NASDAQ Stock Market LLC
Securities registered or to be registered pursuant to Section 12(g) of the Act. None
Table of Contents
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None
Indicate the number of outstand... |
1 | 171199997_3 | 171199997 | filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
x Yes o No
Indicate by chec... |
1 | 171199997_b0 | 171199997 | By: Name: Title:
/s/ Ralf Schmid Ralf Schmid Chief Financial Officer
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
PwC Wirtschaftsprüfung GmbH Erdbergstraße 200 1030 Vienna Austria Tel.: +43 1 501 88 - 0 Fax: +43 1 501 88 - 601 E-mail: office.wien@at.pwc.com www.pwc.at
Exhibit 15.1
We hereby consent to... |
1 | 171199997_b1 | 171199997 | to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report on Form 20-F of Nabriva Therapeutics AG (the "Company") for the year ended December 31, 2015, as filed with the U.S. Securities and Exchange Commission on the date hereof (the "Report")... |
1 | 171202422_0 | 171202422 | DBV Technologies S.A.
Form 20-F
Filed on 28-Apr-2016 Period 31-Dec-2015 Accession number: 0001193125-16-563719
Included Items
1. 20-F: FORM 20-F 2. EX-4.10 3. EX-4.11 4. EX-8.1 5. EX-12.1 6. EX-12.2 7. EX-13.1 8. EX-13.2 9. EX-15.1
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.... |
1 | 171202422_1 | 171202422 | ACT OF 1934
For the transition period from
to
OR
¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission File Number 001-36697
DBV TECHNOLOGIES S.A.
(Exact name of Registrant as specified in its charter and transl... |
1 | 171202422_2 | 171202422 | one ordinary share, nominal value 0.10 per share
Ordinary shares, nominal value 0.10 per share*
Name of each exchange on which registered
The Nasdaq Stock Market LLC
The Nasdaq Stock Market LLC*
* Not for trading, but only in connection with the registration of the American Depositary Shares. Securities registered o... |
1 | 171202422_3 | 171202422 | registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ N... |
1 | 171202422_b0 | 171202422 | Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: April 28, 2016
/s/ Pierre-Henri Benhamou Name: Pierre-Henri Benhamou Title: Chief ... |
1 | 171202422_b1 | 171202422 | ect the company's ability to record, process, summarize and report financial information and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial
reporting.
Date: April 28, 2016
/s/ David Schilansky Name: Dav... |
1 | 171203119_0 | 171203119 | MATERIALISE NV
Form 20-F
Filed on 28-Apr-2016 Period 31-Dec-2015 Accession number: 0001193125-16-564184
Included Items
1. 20-F 2. EX-1.1 3. EX-4.5 4. EX-8.1 5. EX-12.1 6. EX-12.2 7. EX-13.1 8. EX-13.2 9. EX-23.1
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
¨ ... |
1 | 171203119_1 | 171203119 | 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-36515
MATERIALISE NV
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant's name into English)
Kingdom of Belgium
(Jurisdiction of incorporation or organization)
Technologielaan 15, 3001 Leuven, Belgium... |
1 | 171203119_2 | 171203119 | Depositary Shares pursuant to the requirements of the Securities and Exchange Commission.
Securities registered or to be registered pursuant to Section 12(g) of the Act: None.
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None.
The number of outstanding shares of each of... |
1 | 171203119_3 | 171203119 | ¨ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period tha... |
1 | 171203119_b0 | 171203119 | U.S. Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (i) the Report fully complies with the requirements of section 13(a) or 15(d) of the U.S. Securities Exchange Act of 1934, as amended and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition an... |
1 | 171203119_b1 | 171203119 | ):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information and
(b) Any fraud, whether or not material, that involv... |
1 | 171204684_0 | 171204684 | Globant S.A.
Form 20-F
Filed on 29-Apr-2016 Period 31-Dec-2015 Accession number: 0001144204-16-097409
Included Items
1. 20-F: FORM 20-F 2. EX-8.1: EXHIBIT 8.1 3. EX-12.1: EXHIBIT 12.1 4. EX-12.2: EXHIBIT 12.2 5. EX-13.1: EXHIBIT 13.1 6. EX-13.2: EXHIBIT 13.2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGT... |
1 | 171204684_1 | 171204684 | ANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
¨
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
For the transition period from
to
.
Commission file number: 001-36535
GLOBANT S.A. (Exact name of ... |
1 | 171204684_2 | 171204684 | (b) of the Act.
Title of each class Common shares value $ 1.20 per share
Name of each exchange on which registered NYSE
Securities registered or to be registered pursuant to Section 12(g) of the Act.
None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.
None
Indicate th... |
1 | 171204684_3 | 171204684 | registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted ... |
1 | 171204684_b0 | 171204684 | Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned office... |
1 | 171204684_b1 | 171204684 | procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation and
(d) Disclosed in this report any change in the company's internal control over financial reporting that occurred dur... |
1 | 171207873_0 | 171207873 | SEQUANS COMMUNICATIONS
Form 20-F
Filed on 29-Apr-2016 Period 31-Dec-2015 Accession number: 0001193125-16-569245
Included Items
1. 20-F: FORM 20-F 2. EX-1.1 3. EX-4.1(E) 4. EX-4.15 5. EX-4.16 6. EX-4.17 7. EX-4.18 8. EX-8.1 9. EX-12.1 10. EX-12.2 11. EX-13.1 12. EX-13.2 13. EX-15.1
Table of Contents
UNITED STATES S... |
1 | 171207873_1 | 171207873 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
to
OR
¨ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission file number 001-35135
SEQUANS C... |
1 | 171207873_2 | 171207873 | 12(b) of the Act.
Title of each class
American Depositary Shares, each representing one ordinary share, nominal value 0.02 per share Ordinary shares, nominal value 0.02 per share
* Not for trading, but only in connection with the registration of American Depositary Shares.
Securities registered or to be registered p... |
1 | 171207873_3 | 171207873 | registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ¨ No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or fo... |
1 | 171207873_b0 | 171207873 | d) of the Securities Exchange Act of 1934 and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
April 29, 2016
By: /s/ Deborah Choate Name: Deborah Choate Title: Chief Financial Officer
Exhibit 15.1
CONSENT OF INDEP... |
1 | 171207873_b1 | 171207873 | requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
April 29, 2016
By: /s/ Dr. Georges Karam Name: Dr. Georges Karam Title: Chief Execut... |
1 | 171213205_0 | 171213205 | Ferroglobe PLC
Form 20-F
Filed on 02-May-2016 Period 31-Dec-2015 Accession number: 0001193125-16-572914
Included Items
1. 20-F 2. EX-12.1 3. EX-12.2 4. EX-13.1 5. EX-23.1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One)
¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)... |
1 | 171213205_1 | 171213205 |
Ferroglobe PLC
(Exact name of Registrant as specified in its charter)
England and Wales
(Jurisdiction of incorporation or organization)
c/o Legalinx Ltd One Fetter Lane, London, EC4A 1BR +44-800-9758080
(Address of principal executive offices)
Stephen Lebowitz, Chief Legal Officer 600 Brickell Avenue Suite 3100 Miami... |
1 | 171213205_2 | 171213205 | the issuer's classes of capital or common stock as of the close of the period covered by the annual report.
Ordinary Shares (nominal value of $7.50) Class A Ordinary Shares (nominal value of $7.50)
73,759,990 98,078,163
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405... |
1 | 171213205_3 | 171213205 | subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter)... |
1 | 171213205_b0 | 171213205 | design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in th... |
1 | 171213205_b1 | 171213205 | 15(e)) for the company and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those ... |
1 | 171255226_0 | 171255226 | BT GROUP PLC
Form 20-F
Filed on 19-May-2016 Period 31-Mar-2016 Accession number: 0001193125-16-595118
Included Items
1. 20-F 2. EX-1.1 3. EX-4.3 4. EX-4.4 5. EX-4.5 6. EX-7.1 7. EX-12.1 8. EX-12.2 9. EX-13.1 10. EX-15.1 11. EX-15.2
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.... |
1 | 171255226_1 | 171255226 | ANGE ACT OF 1934 OR
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
For the transition period from
to
Commission File Number: 1-08819
BT Group plc
(Exact name of Registrant as specified in its charter)
Not Applicable
(Tr... |
1 | 171255226_2 | 171255226 | : None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the Annual Report:
9,968,127,681 Ordinary Shares, of 5p each
Indicate ... |
1 | 171255226_3 | 171255226 | file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Re... |
1 | 171255226_b0 | 171255226 | high-speed variant of DSL technology. It provides a high headline speed by reducing the length of the access line copper by connecting to fibre at the cabinet. VoIP: voice over internet protocol a method of transporting speech over the internet. VPN: virtual private network a secure way to create an apparent dedic... |
1 | 171255226_b1 | 171255226 | -protocol label switching supports the rapid transmission of data across network routers, enabling modern networks to achieve high quality of service. MVNO: mobile virtual network operator an arrangement where a retailer sells mobile services under its own brand but uses a mobile network owned by another operator t... |
1 | 171260485_0 | 171260485 | NATUZZI S P A
Form 20-F
Filed on 23-May-2016 Period 31-Dec-2015 Accession number: 0001193125-16-598629
Included Items
1. 20-F: FORM 20-F 2. EX-4.4 3. EX-4.5 4. EX-8.1 5. EX-12.1 6. EX-12.2 7. EX-13.1 8. EX-15.1
Table of Contents
Natuzzi S.p.A
Annual Report on Form 20-F 2015
Table of Contents
UNITED STATES SECUR... |
1 | 171260485_1 | 171260485 | Via Iazzitiello 47, 70029, Santeramo in Colle, Bari, Italy
(Address of principal executive offices)
Mr. Vittorio Notarpietro Tel.: +39 080 8820 111 vnotarpietro@natuzzi.com Via Iazzitiello 47, 70029 Santeramo in Colle, Bari, Italy
(Name, telephone, e-mail and/or facsimile number and address of company contact person)
S... |
1 | 171260485_2 | 171260485 | :
As of December 31, 2015 54,853,045 Ordinary Shares
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.1 Yes ¨ No x
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant ... |
1 | 171260485_3 | 171260485 | ). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ¨
Accelerated filer x
Indicate by check... |
1 | 171260485_b0 | 171260485 | ) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.
Date: May 23, 2016
/s/ Vittorio Notarpietro Name: Vittorio Notarpietro Title: Chief Financial Officer
Exhibit 13.1
Certification Pursuant to Section... |
1 | 171260485_b1 | 171260485 | is being prepared (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purpose... |
1 | 171297464_0 | 171297464 | Castle Brands Inc
Form 10-K
Filed on 14-Jun-2016 Period 31-Mar-2016 Accession number: 0001144204-16-108091
Included Items
1. 10-K: FORM 10-K 2. EX-21.1: EXHIBIT 21.1 3. EX-23.1: EXHIBIT 23.1 4. EX-31.1: EXHIBIT 31.1 5. EX-31.2: EXHIBIT 31.2 6. EX-32.1: EXHIBIT 32.1 7. XBRL (render)
UNITED STATES SECURITIES AND EXCH... |
1 | 171297464_1 | 171297464 | le Brands Inc. (Exact name of registrant as specified in its charter)
Florida (State or other jurisdiction of incorporation or organization)
41-2103550 (I.R.S. Employer Identification No.)
122 East 42nd Street, Suite 5000 New York, New York
(Address of principal executive offices)
10168 (Zip Code)
Registrant's tel... |
1 | 171297464_2 | 171297464 | Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
Indicate by check mark whether the registrant has submitte... |
1 | 171297464_3 | 171297464 | filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
¨ Large accelerated filer ¨ Non-accelerated filer
x Accelerated filer ¨ Smaller reporting company
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No þ
The agg... |
1 | 171297464_b0 | 171297464 | (loss) income attributable to 426,268 controlling interests
(807,703) (1,011,271) (1,123,662) (632,402) (590,996) (1,080,513) (1,495,831) (2,516,368) (3,799,742) (8,906,747)
Net (loss) income attributable to $ 426,268 $ (807,703) $
$
$ (632,402) $ (590,996) $
$
$
$
$
common stockholders
(1,011,271) (1,123,66... |
1 | 171297464_b1 | 171297464 | 207,372 18,536,509 16,513,079 16,157,004 15,936,514 13,381,704 11,982,199
Gross profit
8,167,759 6,702,095 7,056,402 6,627,314 6,147,602 5,994,860 4,883,673 4,546,654 $
$
$
28,553,570 21,572,789 17,603,816
Net (loss) income
421,406 (595,911) (682,057) (850,144) (1,102,068) (311,886) (869,464) (1,190,495) (1,706,... |
1 | 171316464_0 | 171316464 | Medtronic Plc
Form 10-K
Filed on 28-Jun-2016 Period 29-Apr-2016 Accession number: 0001613103-16-000093
Included Items
1. 10-K 2. EX-12.1: COMPUTATION OF RATIO OF
EARNINGS TO FIXED CHARGES 3. EX-21: LIST OF SUBSIDIARIES 4. EX-23: CONSENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM 5. EX-24: POWER OF ATTORNEY 6. E... |
1 | 171316464_1 | 171316464 |
Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934.
For the fiscal year ended April 29, 2016.
o
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
For the transition period from __________ to __________
Commission File No. 1-36820
Ireland (... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.